Ameritas Investment Partners’s Acceleron Pharma XLRN Stock Holding History

Ameritas Investment Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,001	Closed	-$360K	–	3187
2020 Q1	$360K	Buy	4,001 +172	+4%	+$13.4K	0.02%	721
2019 Q4	$203K	Hold	3,829	–	–	0.01%	1081
2019 Q3	$151K	Hold	3,829	–	–	0.01%	1219
2019 Q2	$157K	Buy	3,829 +236	+7%	+$9.77K	0.01%	1207
2019 Q1	$167K	Buy	3,593 +341	+10%	+$15K	0.01%	1149
2018 Q4	$142K	Hold	3,252	–	–	0.01%	1160
2018 Q3	$186K	Hold	3,252	–	–	0.01%	1128
2018 Q2	$158K	Hold	3,252	–	–	0.01%	1220
2018 Q1	$127K	Hold	3,252	–	–	0.01%	1344
2017 Q4	$138K	Buy	3,252 +439	+16%	+$16.5K	0.01%	1308
2017 Q3	$109K	Hold	2,813	–	–	0.01%	1408
2017 Q2	$85K	Buy	2,813 +446	+19%	+$12.9K	﹤0.01%	1565
2017 Q1	$63K	Buy	+2,367	New	+$62.4K	﹤0.01%	1697

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameritas Investment Partners's XLRN Position: Q2 2020 in Review

Ameritas Investment Partners sold out of Acceleron Pharma (XLRN) in Q2 2020, closing a stake of 4,001 shares — an estimated $360K sold.

Ameritas Investment Partners first reported a position in XLRN in Q1 2017 and held it in 13 quarters. The position peaked at $360K in Q1 2020. 242 funds tracked by Wall St. Rank hold XLRN as of Q2 2020.

Ameritas Investment Partners reported no remaining Acceleron Pharma position as of Q2 2020 after selling out during the quarter.
Ameritas Investment Partners sold 4,001 Acceleron Pharma shares in Q2 2020, an estimated $360K.
Ameritas Investment Partners first reported a position in Acceleron Pharma in Q1 2017 and held it in 13 quarters.
Ameritas Investment Partners's Acceleron Pharma position peaked at $360K in Q1 2020.
242 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2020.

Based on Ameritas Investment Partners's 13F filing for Q2 2020, filed 5 Aug 2020.